Effects of Tirzepatide vs. Dulaglutide on Cardiorenal Outcomes: SURPASS-CVOT Analysis - report from ACC 2026

from Medical Digest & Congress Report · host Medical Congress News

Professor Steven E. Nissen presents a critical analysis of the SURPASS-CVOT data, comparing the effects of Tirzepatide and Dulaglutide on expanded cardiorenal outcomes in patients at high cardiovascular risk at the ACC 2026 Annual Congress.Video: https://medicaldigest.org/scientific-contents/interview:effects-tirzepatide-vs-dulaglutide-cardiorenal-outcomes-surpass-cvot-analysis

Episode metadata supplied by the publisher feed · Published Apr 15, 2026

Embed this episode

Attribution link and audio player

Ready to play

Effects of Tirzepatide vs. Dulaglutide on Cardiorenal Outcomes: SURPASS-CVOT Analysis - report from ACC 2026

0:00 8:08

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

The 2026 NKBA Bath Trends Report

Apr 1, 2026 ·14m

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 8 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on April 15, 2026.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!